Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc. (SXTP)
Reporting Period: Quarterly period ended June 30, 2025 (2025 Q2)
Business Overview: A specialty pharmaceutical company focused on infectious diseases, primarily commercializing ARAKODA® (tafenoquine) for malaria prevention. The company is developing new indications for babesiosis and other vector-borne diseases. It operates as a single segment with headquarters in Washington, D.C., and a subsidiary in Australia.
Stock Status: The company effected a 1:5 reverse stock split on February 24, 2025. As of August 13, 2025, there were 4,104,469 shares of common stock issued and outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net Revenue | $257,820 | $440,831 |
| Product Revenue | $100,932 | $264,484 |
| Research Revenue | $206,939 | $299,670 |
| Gross Profit | $50,881 | $141,161 |
| Gross Margin | 50.41% | 53.37% |
| Net Loss (Attributable to 60P) | $(1,733,726) | $(3,610,275) |
| Net Loss Per Share (Basic/Diluted) | $(1.25) | $(2.79) |
| Cash and Cash Equivalents | $1,966,930 (as of June 30, 2025) | - |
| Total Debt (SBA EIDL) | $154,249 | - |
| Derivative Liabilities | $776,172 | - |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased significantly compared to the prior year periods, driven primarily by a surge in research revenues ($206,939 in Q2 2025 vs. $728 in Q2 2024). This was due to new contracts with the U.S. Army Medical Materiel Development Activity (USAMMDA) and the University of Kentucky.
- Product Sales: Product revenues decreased 19.2% in Q2 2025 compared to Q2 2024 ($100,932 vs. $124,972) due to a temporary shortage of the 16-ct Arakoda box format. However, for the six-month period, product revenue increased 14.7%.
- Operating Expenses: Total operating expenses decreased 55.9% in Q2 2025 compared to Q2 2024. This was largely due to the absence of a $2.6 million non-cash stock-based compensation charge recorded in Q2 2024 related to the University of Kentucky. General and Administrative (G&A) expenses increased 42.8% due to higher sales, advertising, and investor outreach costs.
- Derivative Liability Impact: The company recorded a loss of $140,447 in Q2 2025 related to the change in fair value of derivative liabilities (contingent milestone payment to Knight Therapeutics), compared to a loss of $1,101 in the prior year quarter.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for one year from the date of issuance. The company has accumulated losses since inception and relies on capital raises to fund operations.
- Liquidity Outlook: As of June 30, 2025, cash was $1.97 million. Management estimates that, including net proceeds of approximately $4.46 million from a July 2025 offering (subsequent event), funds will be sufficient through March 31, 2026, assuming no additional capital raises.
- Subsequent Event (July 2025 Offering): On July 15, 2025, the company closed a registered direct offering raising approximately $4.46 million. This included the sale of common stock, pre-funded warrants, and warrants.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, citing a lack of full-time in-house personnel with technical knowledge for complex transactions, inadequate segregation of duties, and ineffective controls over the period-end reporting process.
- Supply Chain: A temporary shortage of the 16-ct Arakoda box in the U.S. supply chain was mitigated by the introduction of an 8-ct bottle and the importation of Kodatef.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.46 million raised in July 2025 to cover the projected burn rate through March 2026, given the history of operating losses.
- Revenue Sustainability: Assess the duration and renewal likelihood of the USAMMDA and University of Kentucky research contracts that drove the majority of Q2 revenue.
- Product Commercialization: Monitor the resolution of the Arakoda 16-ct box shortage and the market adoption of the new 8-ct bottle format.
- Derivative Liability: Review the valuation assumptions for the $776,172 contingent milestone payment to Knight Therapeutics, which fluctuates based on the probability of a Change of Control or sale of Arakoda.
- Dilution Risk: Evaluate the impact of the July 2025 offering and outstanding warrants (over 2.1 million warrants outstanding as of June 30, 2025) on future share count and ownership dilution.